Scott Plotkin
Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
7
all conditions, ClinicalTrials.gov
NIH grants tied to them
6
3 more share only the name and are not shown
Trial papers
70
PubMed author-name match
Trials
Studies that name Scott Plotkin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:40 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06262113 · A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1Massachusetts General Hospital · completed · Neurofibromatosis 1 · principal investigator
- Ph2NCT05684692 · Screening Trial for Pain Relief in Schwannomatosis (STARFISH)Massachusetts General Hospital · recruiting · Schwannomatosis, Schwannomas, Pain, Chronic · principal investigator
- Ph2NCT04374305 · Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)Scott R. Plotkin, MD, PhD · recruiting · Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma · principal investigator
- Ph2NCT02831257 · AZD2014 In NF2 Patients With Progressive or Symptomatic MeningiomasMassachusetts General Hospital · completed · Neurofibromatosis 2, Meningioma · principal investigator
- Ph2NCT01767792 · Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular SchwannomasUniversity of Alabama at Birmingham · completed · Neurofibromatosis Type 2, Progressive Vestibular Schwannomas · study chair
- Early Ph1NCT00864864 · Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent GlioblastomaMassachusetts General Hospital · completed · Glioblastoma, Brain Tumor · principal investigator
- Early Ph1NCT00657202 · Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1Massachusetts General Hospital · completed · Neurofibromatosis Type 1, Cutaneous Neurofibromas · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Neurofibromatosis and Schwannomatosis Genes Variant Curation Expert Panel (VCEP)U24NS131158 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2024 to 2026 · $286,701 awarded in 2026Same name and institution; not confirmed by an ID
- Training Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2019 to 2025 · $803,367 awarded in 2025Same name and institution; not confirmed by an ID
- Designing clinical trials for cutaneous neurofibromas, an unmet medical need for patients with neurofibromatosis 1R13CA236402 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2019 · $9,898 awarded in 2019Same name and institution; not confirmed by an ID
- Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningiomaR01CA201130 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2016 to 2019 · $389,008 awarded in 2019Same name and institution; not confirmed by an ID
- Enhancing patient engagement in neurofibromatosis clinical trialsR13TR002095 · NCATS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2017 · $10,017 awarded in 2017Same name and institution; not confirmed by an ID
- Developing Endpoints to Facilitate Clinical Trials in Rare DiseasesR13CA203289 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2016 · $9,993 awarded in 2016Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:40 UTC. The ranking covers the 200 most relevant of 70 PubMed records, and a shared surname and initials can bring in a namesake. All 70 on PubMed
- AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.Cancer Cell · 20071,412 citationsRCR 32.0
- Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.J Clin Oncol · 2010425 citationsRCR 10.4
- Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.J Clin Oncol · 2008386 citationsRCR 8.5
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.Proc Natl Acad Sci U S A · 2013287 citationsRCR 8.0
- A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group.N Engl J Med · 1991271 citationsRCR 11.6
- Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.Neuro Oncol · 2015230 citationsRCR 8.3
- Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season.J Infect Dis · 1988216 citationsRCR 8.7
- 207 citationsRCR 7.2
- Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial.J Clin Oncol · 2010205 citationsRCR 7.3
- Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.J Infect Dis · 1995194 citationsRCR 5.8